【摘要】 用本室制备卵巢癌单克隆抗体COC 183 B₂,按武汉生物制品所治疗用单抗要求;经¹³¹I标记,按腹腔及皮下注射,分别应用于13例患者。腹腔注射组中,8例显像情况与手术所见完全符合。3例原发卵巢癌均显像,1例Krukenberg瘤转移卵巢不显像,另4例不显像者均为良性肿瘤;皮下注射组中只1例卵巢粘液性囊腺癌术后化疗后锁骨上淋巴结转移未显像,而瘤组织与COC 183 B₂免疫组化染色亦阴性。T/NT比值5.35～13.7,提示此单抗可用作放免显像、肿瘤定位,鉴别诊断、临床分期及追踪检测等。更多还原

【Abstract】 Monoclonal antibody COC 183 B2 against ovarian carcinoma was prepared in our laboratory andqualified as required for therapeutic use. After ¹³¹I labeling COC 183 B2 was injected intraperitoneally（i. p.） or subcutaneously （s. c.） in 2 groups of patients for radioimmunoimaging （RⅡ）. 8 cases of i.p. group gave the images all corresponding with the findings during operations: 3 positive images inprimary ovarian carcinomas, 1 negative image in Kruenberg tumor metastatic to ovary and 4 negativeimages all in benign tumors. In the 5 s.c. cases only one mucinous ovarian cystadenocarcinoma aftersurgery and chemotherapy with left supraclavicular lymph node metastasis had a negative image andthe immunohistological staining with COC 183 B₂ was also negative. Computor calculated T/NT duringthe radioimmunoimaging was 5.35 to 13.7. The above results suggest that this MAb could be used forRⅡ, tumor localization, which will be of help to presurgical staging, differential diagnosis as well asfollow-up.更多还原